Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Dubai, 21 June 2026 – Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94^th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD despite current standard-of-care treatment. The study found that 2 in 5 people with ASCVD and CKD had CV inflammation, which is associated with an increased risk of major CV events^2,4. 

A second POSEIDON analysis recently published in the European Journal of Heart Failure showed that two in five people with heart failure also have CV inflammation¹. In POSEIDON, CV inflammation was measured and defined by high-sensitivity C-reactive protein (hsCRP) levels ≥2 mg/L¹. hsCRP is the most commonly used and widely available blood test for measuring CV inflammation^4-6. 

Continue reading Cardiovascular Inflammation: A Hidden Risk for Heart Health →